PLRX
Pliant Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$84.20M
P/E Ratio
—
EPS
$-2.43
Beta
1.25
52W High
$1.95
52W Low
$1.09
50-Day MA
$1.26
200-Day MA
$1.43
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and markets new therapies for the treatment of fibrosis and related diseases in the United States. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-148.38M |
| Operating Margin | 0.00% |
| Return on Equity | -61.60% |
| Return on Assets | -30.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.95 |
| Price-to-Book | 0.46 |
| Price-to-Sales (TTM) | 3071.82 |
| EV/Revenue | 1376.69 |
| EV/EBITDA | -2.54 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $61.91M |
| Float | $60.23M |
| % Insiders | 2.38% |
| % Institutions | 77.73% |
Analyst Ratings
Consensus ($2.67 target)
1
Strong Buy5
Hold1
Strong SellData last updated: 4/9/2026